Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
Eline Me CoerverSezgi KaçarOlga CiccarelliMaria Pia SormaniFrederik BarkhofDouglas Lorne ArnoldMenno Michiel SchoonheimZoé LE Van KempenJop MostertZoé Léonie Elise van KempenJoep KillesteinArman EshaghiBernard Mj UitdehaagMarcus Werner KochPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Aging in RRMS is associated with a lower risk of inflammatory disease activity, across different disease durations. Age should be taken into account when designing clinical trials and future research should investigate how age should be integrated into personalized predictions of treatment response and risk profiling.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- multiple sclerosis
- rheumatoid arthritis patients
- clinical trial
- ankylosing spondylitis
- juvenile idiopathic arthritis
- oxidative stress
- phase ii
- phase iii
- study protocol
- randomized controlled trial
- white matter
- current status
- open label
- placebo controlled